u/yannick_salinas
Contributes reviews on supplier material. Based in Ilorin.
member · joined 16 Jul 2025
Overview — page 3 of 3
comment on anyone else notice triple agonist kicking in around week 65 in c/retatrutide · 75 points · 1 year ago
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
comment on reading triple agonist threads from 2024 and half of it aged badly in c/retatrutide · 65 points · 2 years ago
the escalation is where most of the reported trouble sits
comment on [Question] small molecule — what am I missing here in c/orforglipron · 13 points · 2 years ago
Assumed the peptide purity conversations transferred and they do not. Different analytical problem entirely.
comment on [Question] small molecule — what am I missing here in c/orforglipron · 19 points · 2 years ago
nothing containing this is approved anywhere and research material is not for human use
comment on [Lab] QYB orfo — Medutest came back 99.3% against a claimed 99.0% in c/orforglipron · 11 points · 2 years ago
I would not assume the tolerability profile transfers exactly. Similar class effects, different exposure profile.
comment on retatrutide: what the trials say vs what this community says in c/retatrutide · 4 points · 2 years ago
dose escalation in the trials was slow for a reason
comment on [Results] 45 weeks on 10mg, full numbers, ask me anything boring in c/retatrutide · 11 points · 2 years ago
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.